IS8174A - Setnar afleiður indazólýl(indólýl)maleímíðs sem tálmar kínasa - Google Patents

Setnar afleiður indazólýl(indólýl)maleímíðs sem tálmar kínasa

Info

Publication number: IS8174A
Authority: IS; Iceland
Prior art keywords: sub; kinase; indazolyl; indolyl; substitutes
Prior art date: 2003-06-13

Application number

IS8174A

Other languages

English (en)

Inventor

Zhang Han-Cheng

E. Maryanoff Bruce

Ye Hong

Original Assignee

Janssen Pharmaceutica N.V.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-06-13

Filing date

2005-12-09

Publication date

2005-12-09

2005-12-09 Application filed by Janssen Pharmaceutica N.V. filed Critical Janssen Pharmaceutica N.V.

2005-12-09 Publication of IS8174A publication Critical patent/IS8174A/is

Links

108091000080 Phosphotransferase Proteins 0.000 title abstract 3
102000020233 phosphotransferase Human genes 0.000 title abstract 3
IBDXJDUQTQCJOV-UHFFFAOYSA-N 3-(1H-indazol-3-yl)-4-(1H-indol-2-yl)pyrrole-2,5-dione Chemical class C1=CC=C2C(C=3C(=O)NC(C=3C=3NC4=CC=CC=C4C=3)=O)=NNC2=C1 IBDXJDUQTQCJOV-UHFFFAOYSA-N 0.000 title 1
150000001875 compounds Chemical class 0.000 abstract 2
229940127263 dual kinase inhibitor Drugs 0.000 abstract 1
125000005842 heteroatom Chemical group 0.000 abstract 1
-1 indazolyl-substituted pyrroline compounds Chemical class 0.000 abstract 1
229940043355 kinase inhibitor Drugs 0.000 abstract 1
230000001404 mediated effect Effects 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Biomedical Technology (AREA)
Immunology (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Pain & Pain Management (AREA)
Diabetes (AREA)
Dermatology (AREA)
Hematology (AREA)
Psychiatry (AREA)
Oncology (AREA)
Virology (AREA)
Pulmonology (AREA)
Rheumatology (AREA)
Hospice & Palliative Care (AREA)
Vascular Medicine (AREA)
Urology & Nephrology (AREA)
AIDS & HIV (AREA)
Tropical Medicine & Parasitology (AREA)
Molecular Biology (AREA)
Obesity (AREA)
Endocrinology (AREA)
Emergency Medicine (AREA)
Ophthalmology & Optometry (AREA)

IS8174A 2003-06-13 2005-12-09 Setnar afleiður indazólýl(indólýl)maleímíðs sem tálmar kínasa IS8174A (is)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US47851603P	2003-06-13	2003-06-13
PCT/US2004/017375 WO2005000836A1 (en)	2003-06-13	2004-06-01	Substituted indazolyl(indolyl)maleimide derivatives as kinase inhibitors

Publications (1)

Publication Number	Publication Date
IS8174A true IS8174A (is)	2005-12-09

Family

ID=33551833

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IS8174A IS8174A (is)	2003-06-13	2005-12-09	Setnar afleiður indazólýl(indólýl)maleímíðs sem tálmar kínasa

Country Status (22)

Country	Link
US (1)	US7439363B2 (is)
EP (1)	EP1654255B1 (is)
JP (1)	JP2007500748A (is)
KR (1)	KR20060021890A (is)
CN (1)	CN1832940A (is)
AT (1)	ATE406365T1 (is)
AU (1)	AU2004251178A1 (is)
BR (1)	BRPI0411366A (is)
CA (1)	CA2529353A1 (is)
CO (1)	CO5650246A2 (is)
CR (1)	CR8148A (is)
DE (1)	DE602004016174D1 (is)
EA (1)	EA200600032A1 (is)
EC (1)	ECSP056222A (is)
ES (1)	ES2311161T3 (is)
HR (1)	HRP20050991A2 (is)
IL (1)	IL172456A0 (is)
IS (1)	IS8174A (is)
NO (1)	NO20060145L (is)
RS (1)	RS20050915A (is)
WO (1)	WO2005000836A1 (is)
ZA (1)	ZA200600294B (is)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
KR20040016828A (ko)	2000-12-08	2004-02-25	오르토-맥네일 파마슈티칼, 인코퍼레이티드	키나제 저해제로서 인다졸릴-치환된 피롤린 화합물
CA2485527A1 (en) *	2002-05-08	2003-11-20	Janssen Pharmaceutica N.V.	Substituted pyrroline kinase inhibitors
JP2005531607A (ja) *	2002-06-05	2005-10-20	ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ	キナーゼ阻害剤として置換ピロリン
WO2004094422A1 (en) *	2003-03-27	2004-11-04	Janssen Pharmaceutica N.V.	Substituted pyrroline kinase inhibitors
EP2258359A3 (en)	2005-08-26	2011-04-06	Braincells, Inc.	Neurogenesis by muscarinic receptor modulation with sabcomelin
JP2009506069A (ja)	2005-08-26	2009-02-12	ブレインセルス，インコーポレイティド	ムスカリン性受容体調節による神経発生
US20070088019A1 (en) *	2005-09-29	2007-04-19	Han-Cheng Zhang	Macroheterocyclic compounds as kinase inhibitors
US7985756B2 (en)	2005-10-21	2011-07-26	Braincells Inc.	Modulation of neurogenesis by PDE inhibition
US20100216734A1 (en)	2006-03-08	2010-08-26	Braincells, Inc.	Modulation of neurogenesis by nootropic agents
WO2007134136A2 (en)	2006-05-09	2007-11-22	Braincells, Inc.	Neurogenesis by modulating angiotensin
KR101284836B1 (ko)	2006-05-25	2013-07-10	삼성전자주식회사	이동통신시스템에서 자원 할당 맵 구성 방법
BRPI0715160A2 (pt)	2006-08-08	2013-06-11	Sanofi Aventis	imidazolidina-2,4-dionas substituÍdas por arilamimoaril-alquil-, processo para preparÁ-las, medicamentos compeendendo estes compostos, e seu uso
US20100184806A1 (en)	2006-09-19	2010-07-22	Braincells, Inc.	Modulation of neurogenesis by ppar agents
WO2008037266A1 (en) *	2006-09-25	2008-04-03	Universite Libre De Bruxelles	Inhibitors of conventional protein kinase c isozymes and use thereof for treating inflammatory diseases
MX2009006533A (es)	2006-12-19	2009-06-26	Novartis Ag	Derivados de indolil-maleimida como inhibidores de cinasa.
EP2025674A1 (de)	2007-08-15	2009-02-18	sanofi-aventis	Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
WO2010003624A2 (en)	2008-07-09	2010-01-14	Sanofi-Aventis	Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof
WO2010068601A1 (en)	2008-12-08	2010-06-17	Sanofi-Aventis	A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
WO2010099217A1 (en)	2009-02-25	2010-09-02	Braincells, Inc.	Modulation of neurogenesis using d-cycloserine combinations
DK2470552T3 (en)	2009-08-26	2014-02-17	Sanofi Sa	NOVEL, CRYSTALLINE, heteroaromatic FLUORGLYCOSIDHYDRATER, MEDICINES COVERING THESE COMPOUNDS AND THEIR USE
RU2441000C2 (ru) *	2009-11-27	2012-01-27	Общество с ограниченной ответственностью "Молекулярные Технологии"	4-(1-(4-(4-метоксифенилтио)-2,5-диоксо-2,5-дигидро-1н-пирро-3-ил)-1н-индол-3-ил)бутилкарбамимидотиоат и способ его применения
WO2011107494A1 (de)	2010-03-03	2011-09-09	Sanofi	Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
US8933024B2 (en)	2010-06-18	2015-01-13	Sanofi	Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases
US8530413B2 (en)	2010-06-21	2013-09-10	Sanofi	Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215387A (en)	2010-07-05	2012-04-16	Sanofi Aventis	Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201221505A (en)	2010-07-05	2012-06-01	Sanofi Sa	Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215388A (en)	2010-07-05	2012-04-16	Sanofi Sa	(2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
ES2387359B1 (es) *	2011-02-25	2013-08-01	Consejo Superior De Investigaciones Científicas (Csic)	Inhibidores de GSK-3 útiles en enfermedades neurodegenerativas, inflamatorias, cáncer, diabetes y en procesos regenerativos
WO2012120056A1 (de)	2011-03-08	2012-09-13	Sanofi	Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120050A1 (de)	2011-03-08	2012-09-13	Sanofi	Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2683703B1 (de)	2011-03-08	2015-05-27	Sanofi	Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2012120058A1 (de)	2011-03-08	2012-09-13	Sanofi	Mit benzyl- oder heteromethylengruppen substituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
US8710050B2 (en)	2011-03-08	2014-04-29	Sanofi	Di and tri- substituted oxathiazine derivatives, method for the production, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
EP2766349B1 (de)	2011-03-08	2016-06-01	Sanofi	Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2683704B1 (de)	2011-03-08	2014-12-17	Sanofi	Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120054A1 (de)	2011-03-08	2012-09-13	Sanofi	Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
US8809325B2 (en)	2011-03-08	2014-08-19	Sanofi	Benzyl-oxathiazine derivatives substituted with adamantane and noradamantane, medicaments containing said compounds and use thereof
CN102344443A (zh) *	2011-07-15	2012-02-08	南开大学	点击化学合成开环马来酰亚胺类化合物及其在治疗疾病中的应用
WO2013037390A1 (en)	2011-09-12	2013-03-21	Sanofi	6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013045413A1 (en)	2011-09-27	2013-04-04	Sanofi	6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
CN103622964B (zh) *	2013-12-04	2015-09-23	李强	Trigolutesins A在治疗或预防急性心衰药物中的应用
US10220408B2 (en) *	2016-09-12	2019-03-05	The Boeing Company	Variable radius print head end effector
CN108586432B (zh) *	2018-05-31	2020-08-25	温州医科大学	一种3-(吲哚-5-基)-吲唑衍生物及其应用
AU2019318209B2 (en)	2018-08-10	2025-09-25	Diapin Therapeutics, Llc	Tri-peptides and treatment of metabolic, cardiovascular and inflammatory disorders
EP3920885A1 (en)	2019-02-08	2021-12-15	Frequency Therapeutics, Inc.	Valproic acid compounds and wnt agonists for treating ear disorders

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SK75289A3 (en)	1988-02-10	1998-05-06	Hoffmann La Roche	Substituted pyrroles, their use for producing a drug, and the drug on their base
GB8904161D0 (en)	1989-02-23	1989-04-05	Hoffmann La Roche	Substituted pyrroles
US5624949A (en)	1993-12-07	1997-04-29	Eli Lilly And Company	Protein kinase C inhibitors
SE9603283D0 (sv) *	1996-09-10	1996-09-10	Astra Ab	New compounds
AU4929999A (en)	1998-07-30	2000-02-21	Japan Tobacco Inc.	Disubstituted maleimide compounds and medicinal utilization thereof
JP2002527419A (ja)	1998-10-08	2002-08-27	スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー	Ｇｓｋ−３阻害物質としてのピロール−２，５−ジオン類
KR20040016828A (ko)	2000-12-08	2004-02-25	오르토-맥네일 파마슈티칼, 인코퍼레이티드	키나제 저해제로서 인다졸릴-치환된 피롤린 화합물
CA2485527A1 (en)	2002-05-08	2003-11-20	Janssen Pharmaceutica N.V.	Substituted pyrroline kinase inhibitors
RU2004135382A (ru)	2002-06-05	2005-06-27	Янссен Фармацевтика Н.В. (Be)	Замещенные пирролины в качестве ингибиторов киназы
JP2005531607A (ja)	2002-06-05	2005-10-20	ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ	キナーゼ阻害剤として置換ピロリン
WO2004094422A1 (en)	2003-03-27	2004-11-04	Janssen Pharmaceutica N.V.	Substituted pyrroline kinase inhibitors

2004
- 2004-06-01 BR BRPI0411366-7A patent/BRPI0411366A/pt not_active IP Right Cessation
- 2004-06-01 WO PCT/US2004/017375 patent/WO2005000836A1/en not_active Ceased
- 2004-06-01 CA CA002529353A patent/CA2529353A1/en not_active Abandoned
- 2004-06-01 KR KR1020057023946A patent/KR20060021890A/ko not_active Withdrawn
- 2004-06-01 ES ES04754066T patent/ES2311161T3/es not_active Expired - Lifetime
- 2004-06-01 RS YUP-2005/0915A patent/RS20050915A/sr unknown
- 2004-06-01 DE DE602004016174T patent/DE602004016174D1/de not_active Expired - Fee Related
- 2004-06-01 US US10/858,212 patent/US7439363B2/en not_active Expired - Fee Related
- 2004-06-01 CN CNA200480022892XA patent/CN1832940A/zh active Pending
- 2004-06-01 HR HR20050991A patent/HRP20050991A2/xx not_active Application Discontinuation
- 2004-06-01 EP EP04754066A patent/EP1654255B1/en not_active Expired - Lifetime
- 2004-06-01 AU AU2004251178A patent/AU2004251178A1/en not_active Abandoned
- 2004-06-01 EA EA200600032A patent/EA200600032A1/ru unknown
- 2004-06-01 AT AT04754066T patent/ATE406365T1/de not_active IP Right Cessation
- 2004-06-01 JP JP2006533550A patent/JP2007500748A/ja not_active Withdrawn
2005
- 2005-12-08 IL IL172456A patent/IL172456A0/en unknown
- 2005-12-09 IS IS8174A patent/IS8174A/is unknown
- 2005-12-13 EC EC2005006222A patent/ECSP056222A/es unknown
- 2005-12-13 CR CR8148A patent/CR8148A/es not_active Application Discontinuation
- 2005-12-19 CO CO05127381A patent/CO5650246A2/es not_active Application Discontinuation
2006
- 2006-01-10 NO NO20060145A patent/NO20060145L/no not_active Application Discontinuation
- 2006-01-12 ZA ZA200600294A patent/ZA200600294B/xx unknown

Also Published As

Publication number	Publication date
US7439363B2 (en)	2008-10-21
CO5650246A2 (es)	2006-06-30
RS20050915A (sr)	2008-04-04
ECSP056222A (es)	2006-04-19
AU2004251178A1 (en)	2005-01-06
NO20060145L (no)	2006-03-07
CN1832940A (zh)	2006-09-13
ZA200600294B (en)	2007-04-25
HRP20050991A2 (en)	2006-09-30
CR8148A (es)	2008-09-10
DE602004016174D1 (de)	2008-10-09
BRPI0411366A (pt)	2006-07-25
EP1654255B1 (en)	2008-08-27
ATE406365T1 (de)	2008-09-15
EA200600032A1 (ru)	2006-06-30
US20050004201A1 (en)	2005-01-06
JP2007500748A (ja)	2007-01-18
IL172456A0 (en)	2006-04-10
EP1654255A1 (en)	2006-05-10
WO2005000836A1 (en)	2005-01-06
CA2529353A1 (en)	2005-01-06
ES2311161T3 (es)	2009-02-01
KR20060021890A (ko)	2006-03-08

Publication	Publication Date	Title
EA200600032A1 (ru)	2006-06-30	Замещённые производные индазолил (индолил) малеимида в качестве ингибиторов киназ
DK1362047T3 (da)	2006-09-04	Indazolylsubstituerede pyrrolinforbindelser som kinaseinhibitorer
GB0005357D0 (en)	2000-04-26	Compounds
YU84603A (sh)	2006-03-03	Novi inhibitori tirozin kinaze
BR0311821A (pt)	2005-04-05	Derivados de bisindolil-maleimid como inibidores de cinase
WO2009109991A3 (en)	2010-11-25	Novel hydrazide containing tyrosine kinase inhibitors
MY134783A (en)	2007-12-31	Rho-kinase inhibitors
MY142915A (en)	2011-01-31	Rho-kinase inhibitors
ATE334988T1 (de)	2006-08-15	Thieno 2,3-döpyrimidinediones als inhibitoren von t-zellen-proliferation
AU2001235838A1 (en)	2001-09-17	Imidazol derivatives as raf kinase inhibitors
MXPA05013076A (es)	2006-03-09	Compuestos de isoindolina-1-ona como inhibidores de cinasa.
CY1107747T1 (el)	2013-04-18	Υποκατεστημενα τετρακυκλικα παραγωγα πυρρολοκινολονης χρησιμα ως αναστολεις της φωσφοδιεστερασης
WO2006063113A3 (en)	2007-05-10	Ureas as factor xa inhibitors
ZA200500436B (en)	2006-07-26	6-amino-1H-indazole and 4-aminobenzofuran compounds as phosphodiesterase 4 inhibitors
GB0119863D0 (en)	2001-10-10	DNA-PK inhibitors
EA200601106A1 (ru)	2006-12-29	Трициклические имидазопиридины для применения в качестве ингибиторов желудочной секреции
ATE353876T1 (de)	2007-03-15	Substituierte carbazole als inhibitoren von spla2
DE60318089D1 (de)	2008-01-24	Protein-tyrosine-kinase-inhibitoren
EA200100065A1 (ru)	2001-06-25	Производные гидроксамовой кислоты как ингибиторы продуцирования cd23 человека и высвобождения tnf
WO2006063293A3 (en)	2007-07-12	THIOUREAS AS FACTOR Xa INHIBITORS
IL179030A0 (en)	2007-03-08	Indol-2-one derivatives for the treatment of central nervous disorders, gastrointestinal disorders and cardiovascular disorders
EP1900738A3 (en)	2008-04-09	Substituted pyrroline kinase inhibitors